<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925923</url>
  </required_header>
  <id_info>
    <org_study_id>F151006002</org_study_id>
    <nct_id>NCT02925923</nct_id>
  </id_info>
  <brief_title>Ticagrelor Versus Clopidogrel and Eptifibatide Bolus</brief_title>
  <official_title>Ticagrelor Versus Clopidogrel and Eptifibatide Bolus in Patients With Stable or Unstable Angina Undergoing Coronary Intervention: A Randomized Pharmacodynamic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the inhibition of platelet aggregation (i) ticagrelor
      and bivalirudin/heparin versus (ii) clopidogrel, eptifibatide and heparin in patients with
      unstable angina undergoing coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first 30 minutes of PCI procedure is of outmost importance when plaque ruptures and
      platelet activation occurs. Platelet activation and accumulation causes the formation of
      blood clots that may cause heart attack. As a standard of care, the doctor can prescribe
      medications such as are ticagrelor, eptifibatide, clopidogrel, to prevent the formation of
      blood clots.

      100 patients with stable or unstable angina, both male and female, will be randomized to
      either Group A- Ticagrelor and bivalirudin/heparin or Group B- Clopidogrel, eptifibatide and
      heparin administrated immediately before PCI. Platelet function testing and ECG will be
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Platelet Function Testing</measure>
    <time_frame>5 times (baseline, 30 min, 2 h and 4h, and 2 h)</time_frame>
    <description>The primary end-point of the study is to compare a CHANGE in the percentage of inhibition of platelet aggregation (%IPA) at 2 h comparing ticagrelor and bivalirudin or heparin (Group 1) vs. Clopidogrel, eptifibatide bolus, and heparin (Group 2). We will do a non-inferiority analysis to demonstrate that %IPA at 2 h with ticagrelor and bivalirudin or heparin will be non-inferior to that of clopidogrel and eptifabtide bolus and heparin.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Angina, Stable</condition>
  <condition>Angina, Unstable</condition>
  <arm_group>
    <arm_group_label>Ticagrelor and bivalirudin or heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ticagrelor (180 mg) and bivalirudin/heparin (n=50 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel, eptifibatide and heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel (600 mg), eptifibatide (180 mcg/kg) and heparin (n=50 patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, ticagrelor and bivalirudin or heparin will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.</description>
    <arm_group_label>Ticagrelor and bivalirudin or heparin</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptifibatide</intervention_name>
    <description>After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus and heparin will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.</description>
    <arm_group_label>Clopidogrel, eptifibatide and heparin</arm_group_label>
    <other_name>Integrilin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Clopidogrel, eptifibatide and heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable or unstable angina.

        Exclusion Criteria:

          1. need for oral anticoagulation therapy (Warfarin, Dabigatran, Rivaroxaban, Apixaban,
             Edoxaban)

          2. increased risk of bradycardia, and the associated therapy with a strong cytochrome
             P-450 inhibitors (anti-retroviral agents, antifungal agents and some antibiotics eg.
             Indinavir, Nelfinavir, Lopinavir, Ritonavir, Itraconazole, Ketoconazole, Voriconazole,
             Clarithromycin, Telithormycin)

          3. surgery&lt;4 weeks

          4. use of any thienopyridines (Clopidogrel, Prasugrel) 7 days prior to randomization

          5. administration of GP IIb/IIIa inhibitors

          6. bleeding diathesis or major bleeding episode within 2 weeks

          7. thrombocytopenia (Platelet count &lt; 100000)

          8. incessant chest pain

          9. hemodynamic instability (Mean arterial pressure &lt; 65 mm Hg; need for vasopressor or
             inotropic agents; need for mechanical circulatory support for coronary intervention),
             NSTEMI as evidenced by elevation of troponin levels (Troponin &gt; 0.034 ng/ml); renal
             failure with a serum creatinine &gt;2.0 mg/dL

         10. anemia with HCT&lt;30%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massoud Leesar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehak Goel, PhD</last_name>
    <phone>205-975-4021</phone>
    <email>mehakgoel@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massoud Leesar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Massoud Leesar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Eptifibatide</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

